How M.B.A. was paid
$5.5M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Stock | Options | Incentive | Other | Total |
|---|---|---|---|---|---|---|---|
| Bernard Coulie, M.D., Ph.D., M.B.A.President, Chief Executive Officer and Director | $682,000 | — | $1,810,250 | $2,713,750 | $204,600 | $52,301 | $5,462,901 |
| Keith Cummings, M.D., M.B.A.Chief Financial Officer | $503,876 | $201,550 | $631,081 | $946,055 | $100,775 | $14,000 | $2,397,337 |
| Minnie KuoChief Operating Officer | $470,696 | $188,279 | $307,464 | $460,920 | $103,553 | $11,942 | $1,542,854 |
| Éric Lefebvre, M.D.Former Chief Medical Officer | $571,861 | $215,617 | $508,541 | $762,355 | — | $666,486 | $2,724,860 |
What changed and why
- $5.5MBernard Coulie received total compensation of $5,462,901 in fiscal 2025, representing a decrease from the prior year.
- Named executive officers other than the CEO received one-time cash retention awards in 2025.
- $610KEric Lefebvre stepped down as Chief Medical Officer and received $610,456 in severance and related payments.
- Stock and option awards made up the majority of the CEO compensation package for 2025.
- 77.06%Advisory say-on-pay support increased to 77.06% at the 2025 annual meeting following stockholder outreach and program changes.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.